泊马度胺联合低剂量地塞米松治疗来那度胺治疗失败的复发难治多发性骨髓瘤
MM-014试验A队列评估泊马度胺联合低剂量地塞米松用于来那度胺治疗失败后复发难治多发性骨髓瘤患者的安全性和疗效。
核心结论
- 泊马度胺联合低剂量地塞米松在来那度胺治疗失败的复发难治多发性骨髓瘤中显示疗效,支持早期序贯使用泊马度胺方案。
研究设计与样本
- 泊马度胺4 mg第1-21天,28天周期;地塞米松40 mg(>75岁20 mg)第1、8、15、22天。
- 主要终点为总体缓解率,次要终点包括无进展生存期、总生存期和安全性。
临床怎么用
- 对于来那度胺治疗失败的复发难治多发性骨髓瘤患者,可考虑早期使用泊马度胺联合低剂量地塞米松。
- 包括来那度胺难治患者在内,泊马度胺方案仍可带来缓解和生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies. In cohort A of the phase 2 MM-014 trial, we examined the safety and efficacy of pomalidomide plus low-dose dexamethasone immediately after lenalidomide-based treatment failure in patients with RRMM and two prior lines of therapy. Pomalidomide 4 mg was given on days 1 to 21 of 28-day cycles. Dexamethasone 40 mg (20 mg for patients aged >75 years) was given on days 1, 8, 15 and 22 of 28-day cycles. The primary endpoint was overall response rate (ORR), and secondary endpoints included progression-free survival (PFS), overall survival (OS) and safety. The intention-to-treat population comprised 56 patients; all received prior lenalidomide (87·5% lenalidomide refractory) and 39 (69·6%) received prior bortezomib. ORR was 32·1% (28·2% in the prior-bortezomib subgroup). Median PFS was 12·2 months (7·9 months in the prior-bortezomib subgroup). Median OS was 41·7 months (38·6 months in the prior-bortezomib subgroup). The most common grade 3/4 treatment-emergent adverse events were anaemia (25·0%), pneumonia (14·3%) and fatigue (14·3%). These findings support earlier sequencing of pomalidomide-based therapy in lenalidomide-pretreated patients with RRMM, including those who have become refractory to lenalidomide. Trial registration: www.ClinicalTrials.gov identifier NCT01946477.
引用
- Siegel DS, Schiller GJ, Song KW, et al. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. Br J Haematol. 2019. PMID: 31588567. doi:10.1111/bjh.16213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。